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Myogenic factor genes were found to respond differentially to electrical stimulation of denervated chick skeletal muscle. Myogenm gene activity 
de&ted rapidly (tliz: -2 min), comparable to the rate of a~etylcholine r ceptor (AChR) gene Inactivation, while other myogenic bHLH genes either 
lost activity more slowly (MyoD) or not at all (myf5, herculin). Protein kinase C (PKC) is known to couple membrane activity to AChR gene 
inactivation; myogenin gene transcription was also rapidly blocked by the PKC activator PMA, whereas electrostimulation remained without effect 
on myogenin gene activity in muscle that was either exposed to the kinase inhibitor staurosporine or chromcally treated with PMA to deplete PKC. 
These results attest to a special role for myogenin in the activation of AChR genes in denervation su~rsensltivity. 
Excitation-transcription coupling; Protein kinase C; Myogenin; Acetylcholine receptor; Chick skeletal muscle 
1. INTRODUCTION 
Adult skeletal muscle is plastic, i.e. capable of chang- 
ing its phenotype in response to suitable stimuli. Among 
the changes in protein composition that can occur those 
affecting myofibrillar structures, energy metabolism, 
and excitability have been most thoroughly studied [l- 
41. The neural influence on the expression of ace- 
tylcholine receptor (AChR) in particular has been inves- 
tigated [5-71. Promoters of all receptor subunit-encod- 
ing genes investigated so far contain MyoD binding 
sites (‘E boxes’) and are activated by myogenic factors 
[8--171. That these factors may regulate expression of the 
y isoform of the receptor not only during differentiation 
of myogenic cells but also during adaptive changes in 
adult muscle, is attested to by the presence of E boxes 
in activity response elements [18-201 and the effect of 
denervation and electrical stimulation on the levels of 
mRNAs coding for myogenin and MyoD, two promi- 
nent members of the family [21-231. 
We have previously shown that the transcriptional 
activity of receptor subunit genes rises by approxi- 
mately an order of magnitude upon the denervation of 
chick skeletal muscle [24,25] and that electrical stimula- 
tion leads to rapid inactivation of these genes [25]. An 
analysis of mRNA levels revealed that of the myogenic 
factors (MyoD, myogenin, myf5, and herculin), only 
myogenin mimicked the behavior of receptor subunits 
prompting us to propose a regulatory scheme in which 
autoactivation of myogenin plays a central role [23]; we 
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have also shown that protein kinase C (PKC) couples 
membrane electrical activity to inhibition of AChR 
genes [25]. Consequently, if one or the other myogenic 
factor is assumed to control receptor genes in vivo, one 
should expect it to be targeted by PKC as well. Here we 
show that, among myogenic factors, myogenin is 
uniclue in that the dene~ation-induced activity of the 
gene coding for it is rapidly and completely blocked by 
signals from the depolarizing sarcolemma, and that 
these signals are mediated by PKC. 
2. MATERIALS AND METHODS 
2.1. Animal experiments 
Sciatic nerve section and electrical stimulation were performed on 
4-day Leghorn chicks (Hall’s Brothers Hatchery, North Brookfie~d. 
MA) as described previously [25]. Animal care was in accordance with 
institutional guidelines. 
2.2. Transcrtptton elongation analysis 
Nuclei were isolated, and transcript elongation was carried out with 
IO7 freshly prepared or liquid nitrogen-stored nuclei, using 150 ,&i 
[“P]UTP, as described previously [25], except that NaOH treatment 
was omitted and unlabeled UTP was added to a final concentration 
of 150 PM. Nascent transcripts were purified through a Sephadex 
G-50 spun column, followed by TCA and ethanol pr~ipitations. For 
hybridization, aliquots containing a constant amount of radiolabel 
( lo6 cpm) were incubated with -0.1 pug of antisense RNA probe at 
52°C; RNase A digestion and electrophoretic analysis followed the 
procedure of Melton et al. 1271. A detailed description of the ribonu- 
clease protectton verston of the run-on assay is to be pub~ish~ eise- 
where. Results were quantified using a Beta scanner (Ambis, San 
Dtego, CA) and visualized by autoradiography. Riboprobe templates 
for chicken myogenic factors were obtained as described previously. 
Probes for CMDI, the chicken homolog of MyoD (protected region: 
102 nt), and for chicken rnyogenin (protected sequences: 200 and 390 
nt) were derived from cDNA libraries, while short sequences corre- 
sponding to the HLH region of chicken myf5 and herculin (protected 
region: 194 nt) were obtained with the PCR from genomic DNA using 
21 
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suitable primers [23]. The 399-bp HindIII-EcoRI genomic fragment 
of the chicken AChR a-subunit gene, containing exon 7 and flanking 
intron sequences [26], was cloned into the Bluescript plasmid pSK- 
in order to generate riboprobe. CTF4 probe was generated from a 
171 -bp PCR fragment derived from the coding region [28] and cloned 
into pKSII+; the probe protects primary transcripts of 50 and 121 nt. 
The 3’ end of the chicken c-fos cDNA was deleted by restricting 
pTZ19R/ch c-fos with BumHI; the resulting plasmid was linearized 
with EcoRI, and the remaining 5’ fragment ranscribed with T7 (pro- 
tected region: 550 nt). The 3’ end of the chicken myosin light chain 
cDNA was removed by cutting MLClf with SstI; an antisense probe 
was prepared by linearizing the plasmid and transcribing with SP6 
(protected region: 180 nt). 
2.3. Protein kinase C assay 
Nuclear high salt extracts were chromatographed on DEAE-cellu- 
lose. The fraction eluting between 100 and 400 mM NaCl was col- 
lected, and protein determined by the Bradford procedure; aliquots 
containing 1 fig of protein (ca. 5% of sample) were assayed for PKC 
as described previously [25], except hat diolein was omitted from the 
incubation. The assay cocktail contained 20 mM Tris-HCI pH 7.5: 5 
mM magnesium nitrate; and 0.2 mg/ml histone type III (Sigma). When 
included, final concentrations of supplements in the incubation mix- 
ture were: calcium chloride, 1 mM; phosphatidyl serine (Folch fraction 
III from bovine brain, Sigma), 40 &ml; and phorbol 12-mynstate 
13-acetate (PMA) (Sigma), 5 ,uM. 
3. RESULTS 
Fig. 1 shows transcription activities in innervated, 
denervated, and short-term stimulated muscle for all 
myogenic factors and several control genes. Myogenin 
gene activity increases -16-fold upon denervation and 
drops -20-fold upon 2 h of electrostimulation. Of the 
other factor genes, MyoD responds somewhat o these 
treatments, but much less than myogenin, approxi- 
mately doubling in activity after denervation and re- 
turning to control (innervated) levels in stimulated mus- 
cle; no pronounced changes in the activities of the genes 
coding for myf5 and herculin are observed. A strong 
response of AChR subunit genes to membrane activity 
has been described previously [25]. Here results of the 
analysis of the a-subunit gene activity are included; they 
are very similar in rate and extent to the changes in the 
activity of the myogenin gene. The gene coding for the 
E protein CTF4 [28], which might function as a dimer- 
ization partner of a myogenic protein and thereby deter- 
mine its activity, was also investigated, but no change 
in activity was seen (this finding does not rule out the 
possible limitation of maximal AChR gene transcrip- 
tion rate by the E protein). Similarly, the activity of the 
MLC gene is little affected by the experimental manipu- 
lations. The c-fos gene, on the other hand, which is 
stimulated by neuronal activity in the CNS [29-3 11, also 
is somewhat (-30%) activated in skeletal muscle by 
membrane depolarization. 
To check if the myogenin gene, like genes coding for 
AChR subunits, is inhibited by PKC, the effect of the 
intramuscular administration of the phorbol ester PMA 
was examined. The results, shown in Fig. 2, resemble 
those obtained with electrostimulation except that they 
develop more slowly, perhaps as a consequence of the 
gradual penetration of the drug into the tissue, and also 
less completely, suggesting that the data reflect gene 
activities averaged over affected, less affected, and non- 
affected muscle fibers. At any rate, complete inactiva- 
tion is not seen even after considerable time. Appropri- 
ate controls reveal that the effect is not caused by the 
vehicle or by some nonspecific phorbol ester action 
(Fig. 2). 
The effect of blockade of PKC on the activity of 
myogenic factor genes was also investigated. We found 
that the membrane-to-genome signalling pathway was 
interrupted whether the enzyme was (a) acutely blocked 
Period of treatment (mm) 
Fig. 1. Effect of electrostimulation on myogenic factor genes. Transcript elongation was assayed in nuclei isolated from control (innervated) muscle 
(N, ‘normal’) and from muscle denervated for 40 h and stimulated for the indicated periods of time. (A) Autoradiograms of ribonuclease protectlon 
analysis; the signals from the larger ones of the 2 myogenin and CTF4 protected regions (see section 2) are shown. (B) Quantitative analysis. Each 
data point represents the mean of up to 7 independent measurements; standard eviations averaged 5.4% (range: 0.1 to 8.1%). Results are normalized 
to the transcriptional activities in 40-h denervated muscle. About 1 h after the onset of stimulation, myogenin gene activity begins to fall below 
control (innervated muscle) values. 
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with the kinase inhibitor staurosporine or (b) depleted 
from the tissue by prior long-term exposure to phorbol 
esters (Fig. 3). As reported previously [25], the 3-day 
treatment with phorbol ester results in the virtually 
complete disappearance of PKC from skeletal muscle 
nuclei (data not shown). 
The pharmacological experiments strongly suggest 
that PKC mediates the effects of electrical stimulation 
on the myogenin gene. Such a link implies that changes 
in gene activity should either accompany or follow, but 
not precede, changes in PKC activity. This prediction 
is borne out by observation: the rate of kinase activation 
is somewhat faster than the rate of gene inactivation; 5 
min after the onset of stimulation nuclear PKC is about 
60% activated (Fig. 4), while myogenin and a-subunit 
genes are blocked to a somewhat lesser extent (-45%) 
(Fig. 1). Since total (phorbol ester-induced) enzyme ac- 
tivity does not change, the increase in calcium/ 
phosphatidyl serine-dependent protein phosphorylation 
is likely to be the consequence of activation of nuclear 
PKC rather than of translocation of cytosolic enzyme 
into the nucleus. 
4. DISCUSSION 
We have previously reported that the messages cod- 
ing for the AChR a-subunit [32] and myogenin [23] are 
lost from electrically stimulated muscle with rates indis- 
tinguishable from those seen after actinomycin D ad- 
ministration, suggesting asudden arrest of gene activity. 
The present report now confirms by direct gene activity 
analysis that the myogenin gene is indeed inactivated 
following plasma membrane depolarization. These find- 
ings and earlier observations concerning the presence 
and functional significance of E boxes in promoters of 
receptor subunits [g-17,20] and myogenin [33,34]; the 
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Fig. 2. Effect of phorbol ester on myogenic gene activity. Transcript elongation was assayed, as described in the legend to Fig. 1, in nuclei isolated 
from control (N) and denervated muscle, at the indicated times after in vivo administration of 20 pg phorbol 12-myristate 13-acetate (PMA)&l 
20% DMSO in ethanol (v/v), injected intramuscularly. (A) Autoradiograms of ribonuclease protection analysis. (B) Quantitative analysis of time 
course of PMA effect. Each data point represents the mean of 2 to 7 independent measurements; standard deviation averaged 3.4% (range 1 .O to 
6.9%). (C) Quantitative analysis of pharmacological controls. The bar graph shows nuclear run-on data obtained with probes specific for the 
indicated genes. Within each set, results (from left to right) refer to: control (innervated) muscle; 46-h denervated; 40-h denervated/30-min PMA 
treated; 46-h denervated/30-min DMSO (20% DMSO in ethanol (v/v)) treated; and 40-h denervated/30_min 4-ar-phorbol (Sigma; 20 pg in 20 ~1 
of 20% DMSO in ethanol (v/v)) treated muscle. Results are normalized to the transcriptional activities in 40-h denervated muscle. 
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Fig. 3. Effect of blockade of PKC on MyoD and myogenin gene activities m stimulated muscle. At 37 h after denervation, 1 flcg staurosporine (Sigma) 
in 20 91 50% phosphate-buffered saline in ethanol (v/v). or ethanol alone, was injected into the denervated muscle. Three hours later, one group 
of ammals received a 30-mm stimulation while the control group remained unstimulated before being sacrificed. In a parallel experiment, animals 
received a 72-h treatment of PMA or DMSO alone. Similarly. one group received a 30-min stimulation while the control group remained 
unstlmulated. Intramuscular injections of PMA and DMSO were repeated at 24-h intervals. with denervation taking place 32 h after administratlon 
of the first dose of PMA or DMSO (A) Autoradiograms of ribonuclease protectlon assay. (B) Quantitative analysis of staurosporine effect. The 
bar graph shows nuclear run-on data obtained with probes specific for MyoD and myogenin. Within each set, results (from left to right) refer to: 
control (innervated); 40-h denervated; 40-h denervated/30-mm stimulated; 40-h denervated/3-h staurosporine treated; 40-h denervated/3-h stauro- 
sporine treated/30-min stimulated; and 40-h denervated/3-h ethanol treated/30-mm stimulated muscle. Results of run-on assay are presented as % 
of gene activities in denervated muscle. (C) Quantltatlve analysis of PKC depletion effects. Transcription activities of MyoD and myogenin in nuclei 
isolated from (from left to right); control (innervated); 40-h denervated; 40-h denervated/30-min stimulated; 72-h PMA treated/40-h denervated: 
72-h PMA treated/40-h denervated/30-min stimulated: and 72-h DMSO treated/40-h denervated/30_min stimulated muscle. The data are presented 
as 96 of gene actlvlties m denervated muscle. 
autocatalytic activity of MyoD and myogenin [35,36]; 
and kinetic evidence for an autocatalytic loop in dener- 
vation-induced receptor gene upregulation [23], impose 
constraints on models of the regulatory pathway. The 
simplest mechanism assumes that myogenin activates its 
own promoter. In this scheme, whose general outline 
was proposed by Changeux [37] and a myogenin version 
of which was sketched by Neville et al. [23], innervated 
muscle contains low levels of myogenin protein, which, 
as a result of nuclear PKC activity maintained by inter- 
mittent action potentials, is largely phosphorylated and 
consequently inactive. Denervation causes cessation of 
membrane activity; the resulting kinase inactivation and 
gradual dephosphorylation/activation of myogenin 
leads to the activation of myogenin-dependent genes, 
including the gene coding for myogenin itself. Con- 
versely, when denervated muscle is stimulated, nuclear 
24 
PKC is activated within minutes and through phospho- 
rylation of myogenin protein shuts down myogenin- 
dependent genes including those coding for AChR sub- 
units and for myogenin itself. That phosphorylation of 
myogenin by PKC indeed inactivates the factor has re- 
cently been reported [38]. Similarly, in cultured muscle 
cells activation of PKC rapidly leads to a decline of 
MyoD and myogenin mRNAs [39]. 
More complex mechanisms can be envisaged. For 
example, the feedback loop may contain an additional 
link or factor. That an indirect pathway for positive 
autoregulation of myogenin exists which involves the 
muscle-specific enhancer binding factor MEF-2, has 
been proposed by Olson and his collaborators [34,40]; 
the myogenin promoter in the chick as well as in mam- 
mals, in addition to a myogenin-sensitive E box also 
contains an MEF-2 site (TATATTT) which is crucial 
Volume 319, number 1,2 FEBS LETTERS March 1993 
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Fig. 4. Effect of electrostimulation on nuclear PKC activity. PKC 
enzyme activity was measured in nuclei from innervated muscle (N) 
and from muscle denervated for 40 h and stimulated for the indicated 
periods of time. lncubatlon mixtures contained, in addition to sample 
and buffer: calcium, phosphatidyl serine, and PMA (0, l ), calcium 
and phosphattdyl serme (n, A), and no addition (n); filled and open 
symbols refer to 2 independent experiments. 
for muscle-specific activity [33,34]. It is conceivable 
therefore that MEF-2 is inactivated by the depolariza- 
tion-PKC pathway, resulting in the shutting down of 
the myogenin gene and simultaneously of the AChR 
subunit genes. The latter effect, because of the absence 
of a measurable delay, is unlikely to be mediated by a 
depletion of myogenin protein; rather, a direct action of 
MEF-2 on receptor genes has to be postulated. So far 
MEF-2 sites have not been observed in receptor subunit 
promoters. The model nevertheless remains viable be- 
cause neither the processes controlling the activity of the 
MEF-2 protein nor the regulatory regions of AChR 
subunit genes are known in their entirety. Myogenin 
may be subject to additionai controls; thus protein ki- 
nase A also inhibits the activity of this factor [41]. In 
general, schemes in which an as yet unidentified com- 
mon transcription factor plays a role or in which com- 
parable kinetics in changes of gene activity result from 
the coincidence of parallel signalling pathways, al- 
though less likely, cannot be ruled out. 
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